Rosiglitazone-Associated Fractures in Type 2 Diabetes

Kahn, Steven E., Zinman, Bernard, Lachin, John M., Haffner, Steven M., Herman, William H., Holman, Rury R., Kravitz, Barbara G., Yu, Dahong, Heise, Mark A., Aftring, R. Paul, Viberti, Giancarlo, for the A Diabetes Outcome Progression Trial (ADOPT) Study Group·2008·Diabetes Care
DOI 10.2337/dc07-2270

Cited by (544)

Items 501–544 of 544

  1. New pharmacological approaches in type 2 diabetes mellitus
    Kenneth J. Cusi · 2009 · Dialnet (Universidad de la Rioja)
  2. Comment identifier les sujets ages a risque de fracture eligibles a un traitement ? Screening elderly at fracture-risk eligible to a treatment
    J. Lorthiois, Jean Bernard Gauvain · 2010
  3. Fracture Risk After Initiation of Use of Canagliflozin
    Hema Padmanabhan · 2019 · Annals of Internal Medicine
  4. Adipose-tissue derived signals control bone remodelling
    Maria‐Bernadette Madel, He Fu, Dominique D. Pierroz, Mariano Schiffrin, Carine Winkler, Anne Wilson, Cécile Pochon, Barbara Toffoli, Jean‐Yves Jouzeau, Federica Gilardi et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  5. The antidiabetic activity of the new composition “Thigliben” on the experimental dexamethasone diabetes mellitus model in rats
    Наталя Анатоліївна Цубанова, O. H. Berdnyk · 2020 · Clinical pharmacy
  6. 노인 당뇨병 환자의 약물 치료
    홍은경 · 2011
  7. Ostéoporose et diabète
    Lisa Bialé, Camille Glanowski, Chloé Jamakorzyan, Manon Lemée, F. Banal, L. Bordier · 2021 · Médecine des Maladies Métaboliques
  8. Manifestations Rhumatologiques observées au cours du diabète sucré dans le Service de Rhumatologie au CHU du Point G, Bamako, Mali
    B Kadio, H Cissé, SI Pamanta, D Samson, S Hassane, Ah I Cissé · 2021 · Rhumatologie Africaine Francophone
  9. Which antidiabetic drug indications are recommended for geriatric DM patients?
    Edoardo Mannucci · 2021 · Journal of Gerontology and Geriatrics
  10. Bone and Diabetes
    Jakob Starup‐Linde, Søren Gregersen · 2020 · Endocrinology
  11. Safety of Antidiabetic Therapies on Bone
    Beata Lecka‐Czernik, Ann V. Schwartz · 2015 · Springer eBooks
  12. Treating Type 2 Diabetes Mellitus
    Alexandra L. Migdal, Susan Herzlinger, Martin J. Abrahamson · 2017 · Springer eBooks
  13. Treating Type 2 Diabetes Mellitus
    Alexandra L. Migdal, Susan Herzlinger, Martin J. Abrahamson · 2017 · Springer eBooks
  14. Treating Type 2 Diabetes Mellitus
    Alexandra L. Migdal, Martin J. Abrahamson · 2016 · Springer eBooks
  15. Current literature in diabetes
    2008 · Diabetes/Metabolism Research and Reviews
  16. Glitazones accelerate bone loss and increase the risk of fracture in patients with type 2 diabetes mellitus
    &NA; · 2009 · Drugs & Therapy Perspectives
  17. Response: The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone (Diabetes Metab J2012;36:371-8)
    Kwang Joon Kim, Sun Ok Song, Byung‐Wan Lee · 2013 · Diabetes & Metabolism Journal
  18. Posttransplant Bone Loss
    Se‐Min Kim, Lubna Bashir Munshi, Bateel Alamoush, Mone Zaidi, Sol Epstein · 2020 · Elsevier eBooks
  19. Opnieuw rosiglitazon
    , · 2008 · Huisarts en Wetenschap
  20. Nutrition and metabolism
    BM Mishra, Deepak Bhatnagar · 2009 · Current Opinion in Lipidology
  21. Manifestaciones musculoesqueléticas de la diabetes mellitus
    M.-A. Timsit · 2018 · EMC - Aparato Locomotor
  22. Metformin
    Jared M. Campbell · 2018 · Elsevier eBooks
  23. Non-GCs Drug-Induced Osteoporosis
    Hesham Salah Hamoud · 2022 · IntechOpen eBooks
  24. Diabetes Mellitus
    Edoardo Mannucci, Daniele Scoccimarro · 2023 · Practical issues in geriatrics
  25. Pathogenesis of osteoporosis
    Emma O. Billington, Ian R. Reid · 2024 · Elsevier eBooks
  26. Antidiabetic drug utilization pattern, affordability and cost analysis in Iran from 2009 to 2021: A need to revise guideline
    Saman Zartab, Hadi Abbasian · 2025 · PLoS ONE
  27. A Critical Review on Diabetes Mellitus Type 1 and Type 2 Management Approaches: From Lifestyle Modification to Current and Novel Targets and Therapeutic Agents
    Apeksha D. Pawar, Shilpa Balu Rohile, Prof. Shaikh. S. D. · 2025 · International Journal of Advanced Research in Science Communication and Technology
  28. Relationship Between α-Glucosidase Inhibitors Application and Bone Mineral Density in Chinese Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study
    Xiumei Luo, Shangjian Li, Ning Chen · 2025 · Diabetes Metabolic Syndrome and Obesity
  29. Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study
    Kyuho Kim, Seung‐Hyun Ko, Jae‐Seung Yun, Kwan Woo Lee, Eun‐Sook Kim, In‐Kyung Jeong, Jae Hyeon Kim, Sang Yong Kim, Kyu Chang Won, Mi-Kyung Kim et al. · 2025 · Scientific Reports
  30. Potentiel thérapeutique de l'activation du récepteur nucléaire PPARgamma dans la myélofibrose
    Juliette Lambert · 2019 · theses.fr (ABES)
  31. Nanotechnological and material science for diabetics and advanced transdermal delivery
    Anna Voronova · 2021
  32. Peptides de l’immunité innée (défensines et cathélicidines) : expression dans les contextes d’obésité et de diabète de type 2, et lien avec la régulation fonctionnelle des adipocytes médullaires et l’os
    Amélie Paquet · 2024 · theses.fr (ABES)
  33. Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
    Jiayu Liao, Zhaotong Cong, Ke Liu, Hanyun Que, Fang Liu · 2026 · The Innovation Drug Discovery
  34. Rosiglitazone Adjunct to Sertraline for Major Depressive Disorder: A Randomized, Double‐Blind, Placebo‐Controlled Trial
    Ahmad Shamabadi, Reihane Karami, Sherinaz Sadati, Kimia Farahmand, Mohamadjavad Ershadmanesh, Rozhin Moosavi, Fatemeh Rahiminejad, Mohammad Reza Khodaie Ardakani, Shahin Akhondzadeh · 2026 · Depression and Anxiety
  35. The efficacy and safety of combining different commercial Chinese polyherbal preparations with conventional Western drugs in the treatment of diabetic osteoporosis: a network meta-analysis
    Xianjun Ni, Yingting Guan, Shenghao Zhi, Xu Wang · 2026 · Frontiers in Pharmacology
  36. BindingDB Entry 50042654: Discovery of INT131: a selective PPAR¿ modulator that enhances insulin sensitivity.
    BindingDB · 2013 · UC San Diego
  37. BindingDB Entry 50014860: Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.
    BindingDB · 2023 · UC San Diego
  38. BindingDB Entry 50028836: Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma a
    BindingDB · 2010 · UC San Diego
  39. BindingDB Entry 50034500: Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPAR¿ partial agonists.
    BindingDB · 2012 · UC San Diego
  40. BindingDB Entry 50039912: Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPAR¿ modulators.
    BindingDB · 2013 · UC San Diego
  41. BindingDB Entry 50030297: Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
    BindingDB · 2010 · UC San Diego
  42. BindingDB Entry 50012541: Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.
    BindingDB · 2022 · UC San Diego
  43. BindingDB Entry 50034470: Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor¿ (PPAR¿) modulators.
    BindingDB · 2012 · UC San Diego
  44. Diabetes mellitus
    Jochen Seißler · 2010 · Elsevier eBooks